Jennifer Webb, MD
Radiation Oncology · Lansing, MINPI 1396782884
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $646 and has fallen 91.3% since, to $56 in 2025.
Across 83 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$362
- Sirtex Medical Inc$193
- Merck$148
- AstraZeneca$85
- Johnson & Johnson$63
- Takeda Pharmaceuticals U.S.A., Inc.$54
- plus $797 from 31 others
What the payments were for
- Food & beverage$1,703100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 25 | $362 |
| Sirtex Medical Inc | 1 | $193 |
| Merck | 5 | $148 |
| AstraZeneca(2 entities) | 5 | $85 |
| Johnson & Johnson | 4 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $54 |
| Pharmaessentia USA Corporation | 2 | $52 |
| Astellas Pharma US Inc | 2 | $47 |
| Sanofi | 2 | $43 |
| Amgen | 2 | $43 |
| Pharmacosmos Therapeutics Inc. | 2 | $40 |
| Genentech USA, Inc. | 2 | $37 |
| Servier Pharmaceuticals LLC | 2 | $35 |
| Pfizer | 2 | $33 |
| Rigel Pharmaceuticals, Inc. | 2 | $32 |
| Tesaro, Inc. | 1 | $32 |
| Bayer | 2 | $29 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| Beigene USA, Inc. | 1 | $24 |
| Sobi, Inc | 1 | $22 |
| Recordati_rare_diseases_inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Exelixis Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Progenics Pharmaceuticals, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| CTI Biopharma Corp. | 1 | $19 |
| EMD Serono, Inc. | 1 | $18 |
| Blueprint Medicines Corporation | 1 | $18 |
| Taiho Oncology, Inc. | 1 | $17 |
| Emmaus Medical, Inc. | 1 | $17 |
| Coherus Oncology, Inc. | 1 | $16 |
| AbbVie | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $16 |
| G1 Therapeutics, Inc. | 1 | $15 |
| Mirati Therapeutics, Inc. | 1 | $14 |
| Seagen Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,703 in reported general payments places this provider in the 75th percentile of 198 radiation oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SsdSilver Sulfadiazine | 13 | $327 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Lansing
- Brendan CoutuLansing$1K
- Frank ViciniPontiac$231K
- Thomas BoikeClarkston$171K
- Farzan SiddiquiDetroit$72K
- Daniel WahlAnn Arbor$42K
- Daniel ChangAnn Arbor$38K
- Shruti JollyAnn Arbor$30K
- Brandon ManciniGrand Rapids$30K
- Alvaro MartinezFarmington Hills$24K
- James KaneAnn Arbor$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.